Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study
| Autor: | Bernat, John, Holida, Myrl D., Longo, Nicola, Goker-Alpan, Ozlem, Wallace, Eric, Deegan, Patrick B., Tøndel, Camilla, Eyskens, Francois J., Feldt-Rasmussen, Ulla, Hughes, Derralynn, Pisani, Antonio, Rocco, Rossana, Almon, Einat Brill, Alon, Sari, Chertkoff, Raul, Warnock, David G., Waldek, Stephen, Wilcox, William R. |
|---|---|
| Zdroj: | In Molecular Genetics and Metabolism February 2023 138(2) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect